Morton DL - Search Results

1

A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.

Hayashi Y, Hoon DS, Foshag LJ, Park MS, Terasaki PI, Morton DL. Hayashi Y, et al. Among authors: morton dl. Cancer. 1993 Aug 1;72(3):750-9. doi: 10.1002/1097-0142(19930801)72:3<750::aid-cncr2820720319>3.0.co;2-v. Cancer. 1993. PMID: 8334627

2

Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4.

Morisaki T, Yuzuki DH, Lin RT, Foshag LJ, Morton DL, Hoon DS. Morisaki T, et al. Among authors: morton dl. Cancer Res. 1992 Nov 1;52(21):6059-65. Cancer Res. 1992. PMID: 1394231

3

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, et al. Morton DL, et al. Ann Surg. 1992 Oct;216(4):463-82. doi: 10.1097/00000658-199210000-00010. Ann Surg. 1992. PMID: 1417196 Free PMC article. Clinical Trial.

4

Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A.

Hayashi Y, Hoon DS, Park MS, Terasaki PI, Foshag LJ, Morton DL. Hayashi Y, et al. Among authors: morton dl. Cell Immunol. 1992 Feb;139(2):411-25. doi: 10.1016/0008-8749(92)90082-z. Cell Immunol. 1992. PMID: 1733512

5

Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor.

Hoon DS, Banez M, Okun E, Morton DL, Irie RF. Hoon DS, et al. Among authors: morton dl. Cancer Res. 1991 Apr 15;51(8):2002-8. Cancer Res. 1991. PMID: 1901239

6

Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas.

Hoon DS, Okun E, Banez M, Irie RF, Morton DL. Hoon DS, et al. Among authors: morton dl. Cancer Res. 1991 Oct 15;51(20):5687-93. Cancer Res. 1991. PMID: 1913686

7

Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide.

Hoon DS, Foshag LJ, Nizze AS, Bohman R, Morton DL. Hoon DS, et al. Among authors: morton dl. Cancer Res. 1990 Sep 1;50(17):5358-64. Cancer Res. 1990. PMID: 2143687 Clinical Trial.

8

Active specific immunotherapy in malignant melanoma.

Morton DL, Foshag LJ, Nizze JA, Gupta RK, Famatiga E, Hoon DS, Irie RF. Morton DL, et al. Semin Surg Oncol. 1989;5(6):420-5. doi: 10.1002/ssu.2980050608. Semin Surg Oncol. 1989. PMID: 2531908 Review.

9

Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells.

Hoon DS, Ando I, Sviland G, Tsuchida T, Okun E, Morton DL, Irie RF. Hoon DS, et al. Among authors: morton dl. Int J Cancer. 1989 May 15;43(5):857-62. doi: 10.1002/ijc.2910430520. Int J Cancer. 1989. PMID: 2714890

10

A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients.

Morioka N, Kikumoto Y, Hoon DS, Morton DL, Irie RF. Morioka N, et al. Among authors: morton dl. J Immunol. 1994 Dec 15;153(12):5650-8. J Immunol. 1994. PMID: 7527447

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

686 results

Search Page

Filters